Tests blood-marker-guided blood thinners to prevent repeat stroke
Tests blood thinners in adults with acute ischemic stroke and a high heart marker.
Plain-language title generated from the registry record
Registry title: MidregiOnal proatrial natriuretic peptide to guide SEcondary Stroke prevention: The MOSES-study
Key facts
- Where
- Athens, GreeceSee the site
- Phase
- Phase 3
Where in Greece
- Attikon University HospitalAthens, GreeceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitaetsspital Basel
- Trial code
- NCT03961334EU 2024-517600-11-01
- Record updated
- 5 November 2026
- Original description
The overall objective of this study is to demonstrate that the efficacy of DOACs is superior to the standard of care (SOC, i.e. treatment with antiplatelets until study end or until AF is detected) for the prevention of stroke recurrence in MR-proANP selected acute ischemic stroke patients without known AF on admission.Read full original descriptionShow less
MidregiOnal proatrial natriuretic peptide to guide SEcondary Stroke prevention: The MOSES-study. An international, multicentre, randomised-controlled, two-arm, assessor-blinded trial.
The overall objective of this study is to demonstrate that the efficacy of DOACs is superior to the standard of care (SOC, i.e. treatment with antiplatelets until study end or until AF is detected) for the prevention of stroke recurrence in MR-proANP selected acute ischemic stroke patients without known AF on admission.
Inclusion: MR-proANP level ≥200pmol/L within 72 hours from symptom onset, Age ≥ 18 years, Clinical diagnosis of ischemic stroke, Written informed consent according to country specific details.
Exclusion: History of AF, AF on 12-lead ECG on admission or any AF ≥30 seconds during heart-rhythm monitoring prior to randomization; Other condition that require anticoagulant therapy (e.g., venous thromboembolism) as per Investigator’s judgment including therapeutic dose of low-molecularweight heparin or heparin; Strong likelihood to be treated with prolonged (i.e. more than 90 days) dual antiplatelet therapy during the course of the trial (such as coronary stenting, etc.); Patients undergoing planned procedures where therapy with a DOAC is a contraindication (e.g. acute surgery); Previous intracranial symptomatic hemorrhage in the last 24 months; Evidence of severe cerebral amyloid angiopathy if MRI scan performed; Chronic kidney disease with creatinine clearance <30ml/min and or subject who requires haemodialysis or peritoneal dialysis; Known bleeding diathesis (e.g. active peptic ulcer disease, platelet count < 100’000/mm3 or haemoglobin < 8 g/dl or INR ≥ 1.7, documented haemorrhagic tendencies or blood dyscrasias); Active infective endocarditis; Known allergy or intolerance to antiplatelets or DOACs; Female who is pregnant or lactating or has a positive pregnancy test at time of admission; If restricted by national law: Current participation in another drug trial.